Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Leukemia Therapeutics Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Gleevec
  • 1.3.3 Sprycel
  • 1.3.4 Tasigna
  • 1.3.5 Clolar
  • 1.3.6 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Leukemia Therapeutics Market Share by Application (2019-2025)
  • 1.4.2 Hospital
  • 1.4.3 Clinic
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Leukemia Therapeutics Market Size
  • 2.1.1 Global Leukemia Therapeutics Revenue 2014-2025
  • 2.1.2 Global Leukemia Therapeutics Sales 2014-2025
• 2.2 Leukemia Therapeutics Growth Rate by Regions
  • 2.2.1 Global Leukemia Therapeutics Sales by Regions 2014-2019
  • 2.2.2 Global Leukemia Therapeutics Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Leukemia Therapeutics Sales by Manufacturers
  • 3.1.1 Leukemia Therapeutics Sales by Manufacturers 2014-2019
  • 3.1.2 Leukemia Therapeutics Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Leukemia Therapeutics Revenue by Manufacturers (2014-2019)
  • 3.2.2 Leukemia Therapeutics Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Leukemia Therapeutics Market Concentration Ratio (CR5 and HHI)
• 3.3 Leukemia Therapeutics Price by Manufacturers
• 3.4 Key Manufacturers Leukemia Therapeutics Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Leukemia Therapeutics Market
• 3.6 Key Manufacturers Leukemia Therapeutics Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Gleevec Sales and Revenue (2014-2019)
  • 4.1.2 Sprycel Sales and Revenue (2014-2019)
  • 4.1.3 Tasigna Sales and Revenue (2014-2019)
  • 4.1.4 Clolar Sales and Revenue (2014-2019)
  • 4.1.5 Others Sales and Revenue (2014-2019)
• 4.2 Global Leukemia Therapeutics Sales Market Share by Type
• 4.3 Global Leukemia Therapeutics Revenue Market Share by Type
• 4.4 Leukemia Therapeutics Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Leukemia Therapeutics Sales by Application

6 United States

• 6.1 United States Leukemia Therapeutics Breakdown Data by Company
• 6.2 United States Leukemia Therapeutics Breakdown Data by Type
• 6.3 United States Leukemia Therapeutics Breakdown Data by Application

7 European Union

• 7.1 European Union Leukemia Therapeutics Breakdown Data by Company
• 7.2 European Union Leukemia Therapeutics Breakdown Data by Type
• 7.3 European Union Leukemia Therapeutics Breakdown Data by Application

8 China

• 8.1 China Leukemia Therapeutics Breakdown Data by Company
• 8.2 China Leukemia Therapeutics Breakdown Data by Type
• 8.3 China Leukemia Therapeutics Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Leukemia Therapeutics Breakdown Data by Company
• 9.2 Rest of World Leukemia Therapeutics Breakdown Data by Type
• 9.3 Rest of World Leukemia Therapeutics Breakdown Data by Application
• 9.4 Rest of World Leukemia Therapeutics Breakdown Data by Countries
  • 9.4.1 Rest of World Leukemia Therapeutics Sales by Countries
  • 9.4.2 Rest of World Leukemia Therapeutics Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Roche
  • 10.1.1 Roche Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.1.4 Leukemia Therapeutics Product Introduction
  • 10.1.5 Roche Recent Development
• 10.2 GlaxoSmithKline
  • 10.2.1 GlaxoSmithKline Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.2.4 Leukemia Therapeutics Product Introduction
  • 10.2.5 GlaxoSmithKline Recent Development
• 10.3 Novartis
  • 10.3.1 Novartis Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.3.4 Leukemia Therapeutics Product Introduction
  • 10.3.5 Novartis Recent Development
• 10.4 Bristol-Myers Squibb
  • 10.4.1 Bristol-Myers Squibb Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.4.4 Leukemia Therapeutics Product Introduction
  • 10.4.5 Bristol-Myers Squibb Recent Development
• 10.5 Eisai
  • 10.5.1 Eisai Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.5.4 Leukemia Therapeutics Product Introduction
  • 10.5.5 Eisai Recent Development
• 10.6 Biogen Idec
  • 10.6.1 Biogen Idec Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.6.4 Leukemia Therapeutics Product Introduction
  • 10.6.5 Biogen Idec Recent Development
• 10.7 ERYtech Pharma
  • 10.7.1 ERYtech Pharma Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.7.4 Leukemia Therapeutics Product Introduction
  • 10.7.5 ERYtech Pharma Recent Development
• 10.8 Celgene
  • 10.8.1 Celgene Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.8.4 Leukemia Therapeutics Product Introduction
  • 10.8.5 Celgene Recent Development
• 10.9 Genmab
  • 10.9.1 Genmab Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.9.4 Leukemia Therapeutics Product Introduction
  • 10.9.5 Genmab Recent Development
• 10.10 Cephalon
  • 10.10.1 Cephalon Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Leukemia Therapeutics
  • 10.10.4 Leukemia Therapeutics Product Introduction
  • 10.10.5 Cephalon Recent Development
• 10.11 Clavis Pharma
• 10.12 Pfizer

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Leukemia Therapeutics Sales Channels
  • 11.2.2 Leukemia Therapeutics Distributors
• 11.3 Leukemia Therapeutics Customers

12 Market Forecast

• 12.1 Global Leukemia Therapeutics Sales and Revenue Forecast 2019-2025
• 12.2 Global Leukemia Therapeutics Sales Forecast by Type
• 12.3 Global Leukemia Therapeutics Sales Forecast by Application
• 12.4 Leukemia Therapeutics Forecast by Regions
  • 12.4.1 Global Leukemia Therapeutics Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Leukemia Therapeutics Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Leukemia is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells.
In 2019, the market size of Leukemia Therapeutics is 10100 million US$ and it will reach 13700 million US$ in 2025, growing at a CAGR of 3.8% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Leukemia Therapeutics.

This report studies the global market size of Leukemia Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Leukemia Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Roche
GlaxoSmithKline
Novartis
Bristol-Myers Squibb
Eisai
Biogen Idec
ERYtech Pharma
Celgene
Genmab
Cephalon
Clavis Pharma
Pfizer

Market Segment by Product Type
Gleevec
Sprycel
Tasigna
Clolar
Others

Market Segment by Application
Hospital
Clinic

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Leukemia Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Leukemia Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Leukemia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025